MX2022012924A - Modulacion de citotoxicidad de celulas t y terapia relacionada. - Google Patents
Modulacion de citotoxicidad de celulas t y terapia relacionada.Info
- Publication number
- MX2022012924A MX2022012924A MX2022012924A MX2022012924A MX2022012924A MX 2022012924 A MX2022012924 A MX 2022012924A MX 2022012924 A MX2022012924 A MX 2022012924A MX 2022012924 A MX2022012924 A MX 2022012924A MX 2022012924 A MX2022012924 A MX 2022012924A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- modified
- modulation
- c5orf30
- cldnd1
- Prior art date
Links
- 230000003013 cytotoxicity Effects 0.000 title 1
- 231100000135 cytotoxicity Toxicity 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- -1 C5ORF30 Proteins 0.000 abstract 2
- 102100027217 CD82 antigen Human genes 0.000 abstract 2
- 102100026099 Claudin domain-containing protein 1 Human genes 0.000 abstract 2
- 102100031552 Coactosin-like protein Human genes 0.000 abstract 2
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 abstract 2
- 108010055211 EphA1 Receptor Proteins 0.000 abstract 2
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 abstract 2
- 102100030421 Fatty acid-binding protein 5 Human genes 0.000 abstract 2
- 102100031512 Fc receptor-like protein 3 Human genes 0.000 abstract 2
- 102000004961 Furin Human genes 0.000 abstract 2
- 101150111025 Furin gene Proteins 0.000 abstract 2
- 102100028998 Histone-lysine N-methyltransferase SUV39H1 Human genes 0.000 abstract 2
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 abstract 2
- 101000912657 Homo sapiens Claudin domain-containing protein 1 Proteins 0.000 abstract 2
- 101000940352 Homo sapiens Coactosin-like protein Proteins 0.000 abstract 2
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 abstract 2
- 101001062855 Homo sapiens Fatty acid-binding protein 5 Proteins 0.000 abstract 2
- 101000846910 Homo sapiens Fc receptor-like protein 3 Proteins 0.000 abstract 2
- 101000696705 Homo sapiens Histone-lysine N-methyltransferase SUV39H1 Proteins 0.000 abstract 2
- 101001050472 Homo sapiens Integral membrane protein 2A Proteins 0.000 abstract 2
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 abstract 2
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 abstract 2
- 101000583692 Homo sapiens Pleckstrin homology-like domain family A member 1 Proteins 0.000 abstract 2
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 abstract 2
- 101001103771 Homo sapiens Ribonuclease H2 subunit A Proteins 0.000 abstract 2
- 101001092917 Homo sapiens SAM domain-containing protein SAMSN-1 Proteins 0.000 abstract 2
- 101000835928 Homo sapiens Signal-regulatory protein gamma Proteins 0.000 abstract 2
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 abstract 2
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 abstract 2
- 101000820460 Homo sapiens Stomatin Proteins 0.000 abstract 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 abstract 2
- 101000663002 Homo sapiens TNFAIP3-interacting protein 3 Proteins 0.000 abstract 2
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 abstract 2
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 abstract 2
- 101001059220 Homo sapiens Zinc finger protein Gfi-1 Proteins 0.000 abstract 2
- 102100023351 Integral membrane protein 2A Human genes 0.000 abstract 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 abstract 2
- 102100037499 Parkinson disease protein 7 Human genes 0.000 abstract 2
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 abstract 2
- 102100030887 Pleckstrin homology-like domain family A member 1 Human genes 0.000 abstract 2
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 abstract 2
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 abstract 2
- 102100021269 Regulator of G-protein signaling 1 Human genes 0.000 abstract 2
- 101710140408 Regulator of G-protein signaling 1 Proteins 0.000 abstract 2
- 102100021258 Regulator of G-protein signaling 2 Human genes 0.000 abstract 2
- 101710140412 Regulator of G-protein signaling 2 Proteins 0.000 abstract 2
- 102100039493 Ribonuclease H2 subunit A Human genes 0.000 abstract 2
- 102100036195 SAM domain-containing protein SAMSN-1 Human genes 0.000 abstract 2
- 102100025795 Signal-regulatory protein gamma Human genes 0.000 abstract 2
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 abstract 2
- 102100021685 Stomatin Human genes 0.000 abstract 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 abstract 2
- 102100037666 TNFAIP3-interacting protein 3 Human genes 0.000 abstract 2
- 102100024026 Transcription factor E2F1 Human genes 0.000 abstract 2
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 abstract 2
- 102100029004 Zinc finger protein Gfi-1 Human genes 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 108010033990 rab27 GTP-Binding Proteins Proteins 0.000 abstract 2
- 102000006581 rab27 GTP-Binding Proteins Human genes 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4201—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005599.2A GB202005599D0 (en) | 2020-04-17 | 2020-04-17 | Modulation of t cell cytotoxicity and related therapy |
| PCT/EP2021/059989 WO2021209627A1 (en) | 2020-04-17 | 2021-04-16 | Modulation of t cell cytotoxicity and related therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012924A true MX2022012924A (es) | 2023-04-03 |
Family
ID=70859980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012924A MX2022012924A (es) | 2020-04-17 | 2021-04-16 | Modulacion de citotoxicidad de celulas t y terapia relacionada. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230158073A1 (enExample) |
| EP (1) | EP4135725A1 (enExample) |
| JP (1) | JP2023521436A (enExample) |
| KR (1) | KR20230004643A (enExample) |
| CN (1) | CN115697357A (enExample) |
| AU (1) | AU2021255917A1 (enExample) |
| BR (1) | BR112022020819A2 (enExample) |
| CA (1) | CA3175622A1 (enExample) |
| GB (1) | GB202005599D0 (enExample) |
| IL (1) | IL297309A (enExample) |
| MX (1) | MX2022012924A (enExample) |
| WO (1) | WO2021209627A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| CN115058504B (zh) * | 2022-07-14 | 2025-07-04 | 广州医科大学 | 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用 |
| WO2025063257A1 (ja) * | 2023-09-22 | 2025-03-27 | 国立大学法人大阪大学 | 制御性ｔ細胞を製造する方法 |
| GB202417285D0 (en) * | 2024-11-25 | 2025-01-08 | Univ Oxford Innovation Ltd | Expanded t cell population |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2015330898B2 (en) * | 2014-10-08 | 2022-03-10 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
| CA2977106A1 (en) * | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| US12350349B2 (en) * | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| WO2018106972A1 (en) * | 2016-12-07 | 2018-06-14 | La Jolla Institute For Allergy And Immunology | Compositions for cancer treatment and methods and uses for cancer treatment and prognosis |
| EP3606518A4 (en) * | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
| US12226479B2 (en) * | 2017-05-11 | 2025-02-18 | The General Hospital Corporation | Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof |
| CA3067244A1 (en) * | 2017-06-12 | 2018-12-20 | Children's Healthcare Of Atlanta, Inc. | T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies |
-
2020
- 2020-04-17 GB GBGB2005599.2A patent/GB202005599D0/en not_active Ceased
-
2021
- 2021-04-16 IL IL297309A patent/IL297309A/en unknown
- 2021-04-16 KR KR1020227039985A patent/KR20230004643A/ko active Pending
- 2021-04-16 BR BR112022020819A patent/BR112022020819A2/pt unknown
- 2021-04-16 CN CN202180041305.5A patent/CN115697357A/zh active Pending
- 2021-04-16 MX MX2022012924A patent/MX2022012924A/es unknown
- 2021-04-16 US US17/919,135 patent/US20230158073A1/en not_active Abandoned
- 2021-04-16 CA CA3175622A patent/CA3175622A1/en active Pending
- 2021-04-16 AU AU2021255917A patent/AU2021255917A1/en active Pending
- 2021-04-16 WO PCT/EP2021/059989 patent/WO2021209627A1/en not_active Ceased
- 2021-04-16 EP EP21721004.6A patent/EP4135725A1/en not_active Withdrawn
- 2021-04-16 JP JP2022562684A patent/JP2023521436A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL297309A (en) | 2022-12-01 |
| WO2021209627A1 (en) | 2021-10-21 |
| JP2023521436A (ja) | 2023-05-24 |
| US20230158073A1 (en) | 2023-05-25 |
| BR112022020819A2 (pt) | 2022-11-29 |
| CA3175622A1 (en) | 2021-10-21 |
| CN115697357A (zh) | 2023-02-03 |
| AU2021255917A1 (en) | 2022-11-17 |
| KR20230004643A (ko) | 2023-01-06 |
| EP4135725A1 (en) | 2023-02-22 |
| GB202005599D0 (en) | 2020-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020819A2 (pt) | Modulação de citotoxicidade de célula t e terapia relacionada | |
| CL2025002208A1 (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas | |
| PE20220573A1 (es) | Inhibidores de fgfr y metodos de uso de los mismos | |
| AR110567A1 (es) | Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina) | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CL2021002669A1 (es) | (divisional de solicitud 3443-2018) tratamientos de cancer. | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| EP4085919A3 (en) | Compositions and methods to treat cancer | |
| MX2020012799A (es) | Composicion y metodo para tratar el cancer asociado con mutacion del egfr. | |
| UY38476A (es) | Inhibidores de arg1 y/o arg2 | |
| WO2019055880A3 (en) | Method of administration and treatment | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| CO2023017812A2 (es) | Ligandos crbn de (r)-glutarimida y métodos de uso | |
| BR112022001329A2 (pt) | Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo | |
| CL2024002093A1 (es) | Anticuerpos anti-cd73. | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| CL2019002854A1 (es) | Compuesto macrocíclico y sus usos. | |
| CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
| CO2023009635A2 (es) | Conjugado de anticuerpo anti-dll3-fármaco | |
| MX2021015501A (es) | Anticuerpos y metodos de uso. | |
| MX2024012368A (es) | Terapia combinada para el tratamiento del cancer | |
| CR20250056A (es) | Moléculas de unión al antígeno anti-steap1 y sus usos. | |
| BR112023024465A2 (pt) | Usos de um modulador de somatostatina para o tratamento de doença | |
| BR112021024438A2 (pt) | Métodos e composições para tratar câncer com carreadores de fármaco de ligação de colágeno | |
| CL2025001795A1 (es) | Anticuerpo anti-cm bxet, conjugado anticuerpo-fármaco y método de preparación de estos y uso de estos |